AI filing briefs · archive

8-K filings in August 2026, explained

2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

6 of 2,914 briefs match

newest first · times in ET
HUBGHub Group, Inc. Aug 24, 4:35 PM ET

Hub Group receives Nasdaq deficiency notice over delayed Q2 2026 10-Q filing

Negative legal/regulatory Written later 3.017.01

Hub Group received a Nasdaq notice on August 20, 2026 that it is not in compliance with Listing Rule 5250(c)(1) because it has not timely filed its quarterly report for the quarter ended June 30, 2026. The notice has no immediate effect on the listing or trading of the Class A common stock, but the company must submit an updated plan to regain compliance by August 27, 2026, and any further exception is capped at September 14, 2026.

  • Nasdaq notice dated August 20, 2026 cites late Form 10-Q for the quarter ended June 30, 2026 under Listing Rule 5250(c)(1)
  • Company must submit an updated compliance plan to Nasdaq by August 27, 2026
  • Delinquent 2025 Form 10-K and Q1 2026 Form 10-Q have an exception deadline of September 14, 2026
  • Notice has no immediate effect on listing or trading on the Nasdaq Global Select Market
Read the filing on SEC.gov ↗

Pantages Capital Acquisition receives Nasdaq market value notice, 180 days to comply

Negative legal/regulatory Written later 3.01

Pantages Capital Acquisition Corporation received a Nasdaq notice on August 21, 2026, stating that its market value of listed securities has been below the $50 million minimum for 30 consecutive business days. Nasdaq said the notice is only a deficiency notification with no current effect on listing or trading, but the company has until February 17, 2027 to regain compliance or face a possible delisting notice.

  • Nasdaq notice dated August 21, 2026 cites the $50 million minimum market value of listed securities for continued listing on the Nasdaq Global Market.
  • The company also does not meet Nasdaq Listing Rule 5450(b)(3)(A), according to the notice.
  • Compliance Period runs 180 calendar days to February 17, 2027; regaining compliance requires at least $50 million for 10 consecutive business days.
  • The company says it is monitoring its market value and evaluating options, but gives no assurance it will regain or maintain compliance.
Read the filing on SEC.gov ↗
BBGIBEASLEY BROADCAST GROUP INC Aug 24, 4:10 PM ET

Beasley Broadcast Group regains Nasdaq stockholders' equity compliance, matter closed

Neutral legal/regulatory Written later 8.01

Beasley Broadcast Group received written notice from Nasdaq on August 19, 2026, confirming it has regained compliance with the $2,500,000 minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq has closed the matter, and the company's common stock continues to trade on Nasdaq under the ticker BBGI.

  • Nasdaq notice dated August 19, 2026 confirmed compliance with the minimum stockholders' equity requirement.
  • The deficiency was first flagged in a Nasdaq notice received April 13, 2026, under Listing Rule 5550(b)(1).
  • The minimum requirement is $2,500,000 in stockholders' equity for Nasdaq Capital Market companies.
  • Nasdaq has closed the matter, and the common stock remains listed under BBGI.
Read the filing on SEC.gov ↗
CAPRCAPRICOR THERAPEUTICS, INC. Aug 24, 9:25 AM ET

Capricor Therapeutics: FDA extends Deramiocel PDUFA date to November 22, 2026

Negative legal/regulatory Written later 8.01

Capricor Therapeutics said the FDA extended the PDUFA target action date for the Deramiocel Biologics License Application from August 22, 2026 to November 22, 2026, after classifying the company's amendment as a major amendment. The amendment adds 24-month open-label extension data from the Phase 3 HOPE-3 study and seeks review for a refined indication focused on upper limb function, which delays the timing of a possible FDA decision on the therapy.

  • PDUFA target action date moved from August 22, 2026 to November 22, 2026, a three-month extension
  • FDA classified the submission as a major amendment and accepted it for review through CBER
  • Amendment includes 24-month open-label extension data from the HOPE-3 study and a request to review a refined indication focused on upper limb function
  • CEO Linda Marbán said HOPE-3 met its primary endpoint, a statistically significant benefit in upper limb function
Read the filing on SEC.gov ↗
SOCSable Offshore Corp. Aug 24, 6:15 AM ET

Sable Offshore: court finds consent decree violation, imposes $1.449 million penalty, declines shutdown

Mixed legal/regulatory Written later 8.01

A federal court in California ruled in several related cases involving Sable's Santa Ynez Pipeline System. The court found Sable violated the 2020 consent decree by restarting operations without state authorization, imposed a $1.449 million penalty, and declined to order a shutdown because the federal pipeline regulator PHMSA had approved the Restart Plan. The court also denied California's bid for a preliminary injunction against the federal Defense Production Act order, and California filed a notice of appeal on August 20, 2026.

  • Court found Sable violated the Consent Decree by restarting the onshore pipeline without OSFM authorization, but declined to order a shutdown.
  • Court imposed a $1.449 million penalty on the Company.
  • Court denied California's motion for a preliminary injunction against the DPA Order; California filed notice of appeal on August 20, 2026.
  • In a separate case, the court declared the DPA Order bars California Department of Parks and Recreation from suing to stop Sable's onshore operations; defendant filed notice of appeal on August 21, 2026.
Read the filing on SEC.gov ↗
CTKBCytek Biosciences, Inc. Aug 24, 6:01 AM ET

Cytek: jury finds for it on three of four claims in Beckman Coulter patent case

Mixed legal/regulatory Written later 7.018.01

On August 21, 2026, a Delaware federal jury returned a verdict in patent infringement action brought by Beckman Coulter against Cytek Biosciences. The jury found noninfringement and invalidity on three of four asserted claims, but found infringement under the doctrine of equivalents on one claim and awarded $20 million in lost profits and $36.11 million in royalties. The company plans post-verdict motions and may appeal, and says the verdict does not require changes to its current products or operations.

  • Jury found noninfringement and invalidity on three of the four asserted patent claims.
  • On the remaining claim, jury found no literal infringement but found infringement under the doctrine of equivalents.
  • Past damages awarded: $20 million in lost profits and $36.11 million in royalties.
  • Company intends to pursue post-verdict motions and may appeal to the Federal Circuit; it says its products remain available.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.